2748 Assessment of associations between disease stage and toxicity with bevacizumab (BEV) in ICON7, a phase III trial of front-line carboplatin/paclitaxel (CP) ± BEV for ovarian cancer (OC)
Embleton, A.C., Perren, T.J., Cook, A., Kent, E., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Beale, P., Cervantes, A., Farrelly, L., Kaplan, R., Parmar, M. K.B., Oza, A.M.Volume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31514-3
Date:
September, 2015
File:
PDF, 62 KB
english, 2015
File converter
More search results
More benefits 
